{
    "nct_id": "NCT05239143",
    "official_title": "A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects with Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Males or females, Subjects ≥18 years with life expectancy >3 months\n* Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer\n* Must have progressed during or after last therapy, developed intolerance/toxicity to current treatment, or ineligible or refused other existing treatment options, and have measurable disease\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status ≥70%\n* Must have adequate vital organ function within pre-determined parameters\n* Must have archived tumor tissue available or consent to a biopsy collection\n* Must be willing to practice birth control\n* Must have a negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration\n* Must have recovered from toxicities due to prior therapies\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has inadequate venous access\n* Has an active second malignancy (not disease free for at least 5 years) in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma\n* Is pregnant or lactating\n* Has a history of or active autoimmune disease\n* Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy\n* Has an active systemic (viral, bacterial, or fungal) infection\n* Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia\n* Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol\n* Has received anticancer medications within 2 weeks of the time of initiating lymphodepletion\n* Has received immunosuppressive medications within 2 weeks of administration of P-MUC1C-ALLO1, and/or expected to require them while enrolled in the study\n* Has received systemic corticosteroid therapy within 1 week of the administration of P-MUC1C-ALLO1 or is expected to require it during the course of the study\n* Has known CNS metastases or symptomatic CNS involvement\n* Has a history of significant liver disease or active liver disease\n* Has a history of known genetic predisposition to HLH/MAS\n* Has received anti-cancer monoclonal antibody therapy within 4 weeks of initiating LD therapy",
    "miscellaneous_criteria": ""
}